1,162 Shares in Amgen, Inc. (NASDAQ:AMGN) Acquired by Wolff Financial Management LLC

Wolff Financial Management LLC acquired a new position in shares of Amgen, Inc. (NASDAQ:AMGN) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,162 shares of the medical research company’s stock, valued at approximately $214,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Capital Financial Planning LLC acquired a new position in Amgen during the 4th quarter valued at approximately $27,000. Arbor Wealth Management LLC increased its stake in Amgen by 154.5% during the 2nd quarter. Arbor Wealth Management LLC now owns 168 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 102 shares in the last quarter. Next Capital Management LLC acquired a new position in Amgen during the 4th quarter valued at approximately $33,000. C J Advisory Inc acquired a new position in Amgen during the 1st quarter valued at approximately $40,000. Finally, Clarfeld Financial Advisors LLC acquired a new position in Amgen during the 4th quarter valued at approximately $41,000. Hedge funds and other institutional investors own 77.50% of the company’s stock.

In related news, Director Ronald D. Sugar sold 2,000 shares of the stock in a transaction on Wednesday, July 3rd. The shares were sold at an average price of $187.58, for a total transaction of $375,160.00. Following the sale, the director now directly owns 16,336 shares of the company’s stock, valued at $3,064,306.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.25% of the company’s stock.

A number of research analysts have issued reports on the stock. Royal Bank of Canada restated a “neutral” rating and set a $192.00 price target on shares of Amgen in a research note on Tuesday, May 21st. Credit Suisse Group assumed coverage on shares of Amgen in a research note on Monday, May 20th. They set an “outperform” rating and a $208.00 price target on the stock. Mizuho restated a “buy” rating and set a $208.00 price target on shares of Amgen in a research note on Monday, July 1st. Oppenheimer set a $210.00 price target on shares of Amgen and gave the company a “buy” rating in a research note on Friday, May 24th. Finally, JPMorgan Chase & Co. restated a “hold” rating and set a $190.00 price target on shares of Amgen in a research note on Wednesday, May 15th. Eight equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $210.41.

Shares of NASDAQ:AMGN traded up $1.22 during midday trading on Friday, reaching $187.22. The company’s stock had a trading volume of 2,963,649 shares, compared to its average volume of 2,814,827. The firm has a market capitalization of $111.54 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 2.22 and a beta of 1.19. Amgen, Inc. has a twelve month low of $166.30 and a twelve month high of $210.19. The firm has a fifty day moving average price of $180.90. The company has a debt-to-equity ratio of 2.58, a current ratio of 2.89 and a quick ratio of 2.53.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, July 30th. The medical research company reported $3.97 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.58 by $0.39. The firm had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 33.78% and a return on equity of 76.17%. The business’s quarterly revenue was down 3.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.83 earnings per share. Equities analysts predict that Amgen, Inc. will post 14.23 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 6th. Stockholders of record on Thursday, August 15th will be paid a $1.45 dividend. This represents a $5.80 dividend on an annualized basis and a dividend yield of 3.10%. Amgen’s payout ratio is currently 40.28%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells.

Read More: Why does the United States have a lingering trade deficit?

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.